Kronos Bio, Inc.

General Information
Business:

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Our lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that has been tested in 148 acute myeloid leukemia (AML) patients. Based on clinical results in a biomarker-defined subset of patients and subject to discussions with regulatory agencies that we intend to have in the first half of 2021, we plan to initiate a registrational Phase 2/3 clinical trial in 2021 in newly diagnosed AML patients with NPM1 mutations, with an anticipated data readout in 2023.

Industry: Pharmaceuticals
Employees: 45
Founded: 2017
Contact Information
Address 1300 So. El Camino Real, Suite 300 San Mateo, California 94402
Phone Number (650) 781-5200
Web Address http://www.kronosbio.com/
View Prospectus: Kronos Bio, Inc.
Financial Information
Market Cap $921.4mil
Revenues $0 mil (last 12 months)
Net Income $-25.1 mil (last 12 months)
IPO Profile
Symbol KRON
Exchange NASDAQ
Shares (millions): 13.2
Price range $19.00 - $19.00
Est. $ Volume $250.8 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Cowen/ Piper Sandler
CO-Managers
Expected To Trade: 10/9/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change